John L. Higgins - 15 Feb 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
By: Charles S. Berkman For: John L. Higgins
Issuer symbol
LGND
Transactions as of
15 Feb 2022
Net transactions value
-$732,557
Form type
4
Filing time
16 Feb 2022, 19:23:37 UTC
Previous filing
28 Jan 2022
Next filing
09 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Tax liability $240,681 -1,946 -0.56% $123.68 344,570 15 Feb 2022 Direct F1
transaction LGND Common Stock Tax liability $254,904 -2,061 -0.6% $123.68 342,509 15 Feb 2022 Direct F2
transaction LGND Common Stock Tax liability $236,971 -1,916 -0.56% $123.68 340,593 15 Feb 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019.
F2 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020.
F3 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021.